Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer Trial 22933

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3143-3149

  Miralbell, Raymond ^a   Mornex, Françoise ^a   Greiner, Richard ^a   Bolla, Michel ^a   Storme, Guy ^a   Hulshof, Maarten ^a   Bernier, Jacques ^a   Denekamp, Juliana ^a   Rojas, Ana M ^a   Pierart, Marianne ^a   van Glabbeke, Martine ^a   Mirimanoff, René O ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; CORTICOSTEROID; NICOTINAMIDE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY; SKIN TOXICITY; TUMOR GROWTH;

EID: 0032887406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3143     Document Type: Article

References (20)

1. Black PM: Brain tumors. N Engl J Med 324:1555-1564, 1991
2. Walker MD, Alexander E, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic glioma: A cooperative clinical trial. J Neurosurg 49:333-343, 1978
3. Kristiansen K, Hagen S, Kollevold T, et al: Combined modality therapy in operated astrocytoma grade III and IV. Cancer 47:649-652, 1981
4. Taghian A, Ramsay J, Allalunis-Turner J, et al: Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 25:243-249, 1993
5. Shibuya M, Ito S, Miwa T, et al: Proliferative potential of brain tumors: Analysis with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Cancer 71:199-206, 1993
6. Kayama T, Yoshimoto T, Fujimoto S, et al: Intratumoral oxygen pressure in malignant brain tumors. J Neurosurg 74:55-59, 1991
7. Rampling R, Cruickshank G: Direct measurements of the pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29:427-431, 1994
8. Keim H, Potthoff PC, Schmidt K, et al: Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiother Oncol 9:21-26, 1987
9. Thames DH, Peters LJ, Withers RH, et al: Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int J Radiat Oncol Biol Phys 9:127-138, 1983
10. Kjellen E, Joiner MC, Collier JM, et al: A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother Oncol 22:81-91, 1991
11. Rojas A, Hirst VK, Calvert AS, et al: Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Bio Phys 34:357-365, 1996
12. Rojas A: ARCON: Accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol 24:174-178, 1992 (suppl)
13. Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993
14. González-González D, Menten J, Bosch DA, et al: Accelerated radiotherapy in glioblastoma multiforme: A dose searching prospective study. Radiother Oncol 32:98-105, 1994
15. Fatigante L, Ducci F, Cartei F, et al: Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: A new modality treatment. Int J Radiat Oncol Biol Phys 37:499-504, 1997
16. Pickles T, Grahem P, Syndikus I, et al: Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother Oncol 40:245-247, 1996
17. Van der Maazen RWM, Thijssen HOM, Kaanders JHAM, et al: Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol 35:118-122, 1995
18. Buatti JM, Marcus RB Jr, Mendenhall WM, et al: Accelerated hyperfractionated radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 34:785-792, 1996
19. Scott CB, Scarantino C, Urtasun R, et al: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55, 1998
20. Werner-Wasik M, Scott CB, Nelson DF, et al: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation Therapy Oncology Group study 83-02. Cancer 77:1535-1543, 1996